Skip to main content

Advertisement

Table 2 Percentage of difference of PET parameters in responder group

From: A phase II clinical trial to investigate the effect of pioglitazone on 18F-FDG uptake in malignant lesions

Type of lesions SUVmax SUVmean Isocontour (Bq/mL) Isocontour-mediastinal
activity(Bq/mL)
Malignant lesion 13.82* 9.49* 19.62*,** 20.37*
Gastrointestinal cancer 25.94* 9.69 33.19* 41.59*
Hepatobiliary and pancreatic cancer 5.89 10.71* 14.40* 8.73
Hepatocellular carcinoma 7.48 3.98 2.83 5.49
Inflammatory lesion 5.95 −1.27 8.91 −14.99
  1. *P < 0.05 when compared parameters between the first day and second day
  2. **P < 0.05 when compared with difference (%) of inflammatory lesion